AstraZeneca PLC (AZN)vsMiMedx Group Inc (MDXG)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
MDXG
MiMedx Group Inc
$3.36
+8.91%
HEALTHCARE · Cap: $458.33M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 13931% more annual revenue ($58.74B vs $418.63M). AZN leads profitability with a 17.4% profit margin vs 11.6%. AZN appears more attractively valued with a PEG of 1.54. MDXG earns a higher WallStSmart Score of 74/100 (B).
AZN
Buy64
out of 100
Grade: C+
MDXG
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for MDXG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Attractively priced relative to earnings
Earnings expanding 99.5% YoY
Every $100 of equity generates 22 in profit
Reasonable price relative to book value
Revenue surging 27.1% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : MDXG
The strongest argument for MDXG centers on P/E Ratio, EPS Growth, Return on Equity. Revenue growth of 27.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : MDXG
The primary concerns for MDXG are Market Cap, PEG Ratio.
Key Dynamics to Monitor
AZN profiles as a value stock while MDXG is a growth play — different risk/reward profiles.
MDXG carries more volatility with a beta of 1.65 — expect wider price swings.
MDXG is growing revenue faster at 27.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
MDXG scores higher overall (74/100 vs 64/100) and 27.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
MiMedx Group Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?